NanoViricides Культура компании

Dr. Jayant Tatake, also known as Jay, Ph.D. has been a Vice President of Research and Development at Nanoviricides, Inc. since January 31, 2006. Dr. Tatake is an organic chemist with over 25 years of experience in Research and Process Development of fine chemicals. His experience encompasses production scale-up and large scale manufacture of raw materials for pharmaceuticals. Before joining NanoViricides, Inc., he served as Assistant Director, Analytical Chemistry at Interpharm Inc. Prior to that, he served as Director of Analytical Services at Pharmax Group, Inc. Dr. Tatake has several years experience in Analytical methods development and Quality Control in cGMP environment. His experience includes bio-analytical methods development. Prior to Pharmax Group, he was in the Pharmacology Department, University of Connecticut Health Center, where he synthesized and developed novel bio-conjugates for bio-diagnostics applications. His expertise includes Organic and Polymer Chemistry, development of multi-step chemical syntheses and processes for the scaling up to large-scale manufacturing. Dr. Tatake is also the author of numerous scientific journal articles. He is a member of American Chemical Society (ACS). He has published several papers in leading journals and is a co-inventor of several patents. Dr. Tatake holds a Ph.D. in Organic Chemistry from Bombay University, Bombay, India, a premier university in the chemical sciences.

Dr. Anil R. Diwan, Ph.D., has been the Chairman and President of NanoViricides, Inc. since June 1, 2005 and serves as its Secretary. Dr. Diwan has been the Chief Executive Officer of All Excel, Inc. since 1995 and TheraCour Pharma, Inc. since 2004. He is the original inventor of the technologies licensed to NanoViricides Inc. as well as the TheraCour polymeric micelle technologies and products based on them. Since 1992, he has researched and developed TheraCour nanomaterials. Dr. Diwan has extensive product development experience while raising financing from collaborations, SBIR grants, other revenues. He has extensive experience in a number of bio-pharmaceutical, biosciences and biomedical fields and technologies that leads to his novel, integrative approach in solving problems with low costs, high innovation and world-leading feature sets. Dr. Diwan is the inventor, developer and principal investor of TheraCour technologies. He has over 18 years of Bio-Pharmaceuticals R&D experience with 12 years as an entrepreneur. He has been a Director of All Excel, Inc. since 1995 and TheraCour Pharma, Inc. since 2004. He holds a US patent on his older polymeric micelle technologies, with his colleagues at University of Massachusetts. Dr. Diwan has continued to work further in the field, to develop nanomaterials that are capable of multi-specific multi-targeting of viruses and at the same time capable of encapsulating active pharmaceutical ingredients (API) in industry-leading payload capacities. He has held several scholastic distinctions, including an All-India 9th rank on the Joint Entrance Examination of all IIT's. Dr. Diwan holds a Ph.D. in Biochemical Engineering from Rice University, TX in 1986 and B.S. degree in Chemical Engineering from Indian Institute of Technology (IIT) Bombay in 1980 and has consistently held high scholastic ranks and honors.

Ms. Meeta R. Vyas, SB, MBA, has been the Chief Financial Officer at NanoViricides, Inc. since May 13, 2013. Ms. Vyas served as a Director of Performance Improvement at Kamylon Capital, LLC. She has over 25 years of cross functional leadership experience ranging from process engineering, investment evaluation, general management and consulting to private equity backed portfolio firms and major non-profits. Ms. Vyas served as the Chief Executive Officer and Vice Chairman of Signature Brands USA, Inc., and Signature Brands, Inc., since September 1997, where she drove significant operations and top line initiatives which led to an eventual sale of Signature Brands to Sunbeam Corporation. She served as Acting Chief Operating Officer at Signature Brands, Inc. She served as a Senior Executive with General Electric Co., where she led a number of continuous improvement initiatives in manufacturing, new product introduction and supply chain management. Ms. Vyas later served as a General Manager of GE Appliances??? Range Products, where she helped double operating income of over a two year period. Beginning in 1991, she held several senior positions with GE including a General Manager of GE Corporate Business Development; a General Manager of GE Appliances; and a Manager of GE Corporate Business Development. Ms. Vyas has also served at Exxon Chemical and Fisher Brothers. Prior to 1991, she was a Consultant with McKinsey & Co., Inc., where she worked primarily with its industrial clients. Most recently, Ms. Vyas has held key leadership roles in two non-profit organizations, the World Wildlife Fund of India and The National Audubon Society as well as providing consulting services to a variety of private equity portfolio firms and non-profit boards. She become the Chief Executive Officer of the World-Wide Fund for Nature - India (WWF-India) and then Vice President of the National Audubon Society (USA), both non-revenue generating entities. She received with a B.S. in Chemical Engineering from MIT and an M.B.A. in Finance from Columbia University.

Dr. Randall W. Barton, also known as Randy, Ph.D. has been the Chief Scientific Officer of NanoViricides, Inc. since June 2005 and serves as its Chief Regulatory Officer. Dr. Barton served as Vice President of Drug Discovery of A&G Pharmaceutical, Inc. He is an expert in receptor-based drug development was most recently the Director of In-vitro Cardiovascular Research at Boehri Ingelheim Pharmaceuticals, Inc. He has almost 20 years with Boehringer Ingelheim Pharmaceuticals. At Boehringer Ingelheim, he was responsible for establishing in vitro drug discovery in cardiovascular research with a partial focus on exploiting immune & inflammatory mechanisms. His work encompassed therapeutic target identification, evaluation, validation, & implementation involving molecular, biochemical & cellular research for lead optimization of both small molecules and biological drug candidates. Dr. Barton was Director of a group responsible for gene therapy, monoclonal antibody and biological drug discovery involving target ID, validation & implementation. This work encompassed both in vitro and in vivo lead optimization & evaluation. His work in immunological and inflammatory diseases involved both small molecule and monoclonal antibody drug candidates targeting tyrosine kinases, proteases and cell surface molecules involved in leukocyte activation an migration. He has served in the military in the Department of Gastroenterology at the Walter Reed Army Institute of Research. Dr. Barton led interdisciplinary drug discovery teams and research groups focused on target identification and evaluation as well as lead optimization of both small-molecule and drugbiological candidates, including gene and cell therapy. Complementing his extensive experience in early- and late-stage drug discovery research as well as management of research and product development teams, he is seasoned in collaboration alliances, licensing deals and patent portfolio evaluation and management. He held a faculty position at the University of Connecticut. He is the author of more than 75 publications and an inventor on eight issued U.S. patents. He holds 5 US patents and has 3 patent applications in progress. He has over 60 scientific publications. Dr. Barton received an AB from Indiana University and a Ph.D. in immunology from the University of Tennessee, Oak Ridge National Laboratory's Oak Ridge Graduate School of Biomedical Sciences.